In wake of unexpected patient deaths, MacroGenics closes down PhII cancer trial
MacroGenics is abruptly shutting down a Phase II trial of its lead experimental drug after seven patients died in the trial.
All 62 patients enrolled in the trial had recurrent or metastatic squamous cell carcinoma of the head and neck. They were split into two arms to test different combinations of enoblituzumab, MacroGenics’ B7-H3-directed antibody, as a first-line treatment. Enoblituzumab was paired with either retifanlimab (anti-PD-1 antibody) or tebotelimab (PD-1/LAG-3 bispecific).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.